• Disc Medicine Inc IRON.OQ reported a quarterly adjusted loss of $1.64​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -89 cents. The mean expectation of thirteen analysts for the quarter was for a loss of $1.74 per share. Wall Street expected results to range from $-1.61 to $-1.18 per share.

• Reported revenue was zero​; analysts expected zero.

• Disc Medicine Inc's reported EPS for the quarter was a loss of $1.64​.

• The company reported a quarterly loss of $60.53 million.

• Disc Medicine Inc shares had fallen by 15.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 19.2% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Disc Medicine Inc is $100.00, about 33.1% above its last closing price of $66.89

This summary was machine generated from LSEG data February 26 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)